Abstract
In patients with operable early breast cancer, neoadjuvant systemic treatment (NST) is a standard approach. Indications have expanded from downstaging of locally advanced breast cancer to facilitate breast conservation, to in vivo drug-sensitivity testing. The pattern of response to NST is used to tailor systemic and locoregional treatment, that is, to escalate treatment in nonresponders and de-escalate treatment in responders. Here we discuss four questions that guide our current thinking about ‘response-adjusted’ surgery of the breast after NST.
Original language | English (US) |
---|---|
Pages (from-to) | 61-71 |
Number of pages | 11 |
Journal | Annals of Oncology |
Volume | 31 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2020 |
Keywords
- breast cancer
- individualized treatment
- neoadjuvant systemic therapy
- oncology
- surgery
ASJC Scopus subject areas
- Hematology
- Oncology